Expanding Oral Options in Psoriasis: Icotrokinra and Beyond

Michael Payette, MD, discusses systemic psoriasis treatment, patient selection, special-site disease, and shared decision-making.

James Song, MD, discusses treatment durability, early intervention, and interpreting long-term clinical trial data in psoriasis.

Adam Friedman, MD, discusses PsA screening, comorbidities, early systemic intervention, and individualized oral therapy selection in psoriasis.

Andrew Blauvelt, MD, MBA, discusses how to interpret head-to-head, indirect, and long-term efficacy data for emerging oral psoriasis therapies.

Adam Friedman, MD, discusses early psoriatic arthritis screening and why long-term data are critical to guiding treatment decisions.